Objective: Long-term treatment with topiramate reduces body weight and improves insulin sensitivity in obese humans. Our aim was to evaluate the effect of topiramate treatment for 4 weeks on insulin sensitivity and secretion, independent of weight loss. Design: Randomized, double-blind, crossover, placebo-controlled study. Methods: Thirteen obese (BMI 36.6G1.3 kg/m 2 (meanGS.E.M.)), insulin-resistant (homeostasis model of assessment-insulin resistance 2.0G0.2) women received topiramate (T, maximum dose of 75 mg) and placebo (P) for 4 weeks, separated by a 4-week washout period. Insulin sensitivity and b-cell function were assessed using a two-step hyperinsulinemic euglycemic clamp with stable isotopes and a hyperglycemic clamp. Results: Hepatic and peripheral insulin sensitivities were not affected by topiramate treatment (glucose disposal rate (step 1 (insulin infusion rate 10 mU/m 2 per min) T: 17.5G0.8 vs P: 18.5G1.0 mmol/kg LBM per min, tZ1.016, PZ0.33; step 2 (insulin infusion rate 40 mU/m 2 per min) T: 27.9G3.2 vs P: 28.8G1.9 mmol/kg LBM per min, tZ0.418, PZ0.68)). Subjects lost a small amount of weight during the topiramate period (T: K1.0G0.2 vs P: K0.1G0.2 kg, tZ2842, PZ0.15). There were no changes in body fat mass, blood pressure, and fasting glucose. b-Cell function was not affected by topiramate as evidenced by an unaltered area under the curve of early (0-10 min; T: 1929.6G265.7 vs P: 2024.7G333.6 pmol/l, tZK0.357, PZ0.73) and late (80-120 min; T: 28 017.7G5029.9 vs P: 31 567.7G5376.2 pmol/l, tZK1.481, PZ0.16) phase insulin levels during hyperglycemia. The use of topiramate was associated with significant side effects such as paresthesia, nausea, dizziness, and concentration problems. Conclusions: Low-dose topiramate treatment for 4 weeks, relative to placebo, had no significant effect on insulin sensitivity in overweight/obese adult females without established diabetes.
Introduction
Topiramate is a broad-spectrum neurotherapeutic agent approved for selected seizure disorders and migraine prophylaxis. A potential beneficial side effect is the dosedependent reduction in body weight, which was verified in healthy obese subjects (1, 2, 3, 4) . Moreover, animal studies show that topiramate has an insulin-sensitizing effect and improves obesity-associated b-cell dysfunction in rats, independently of any reduction in food intake and weight loss (5, 6, 7, 8) . In obese type 2 diabetes (T2DM) patients, long-term topiramate treatment led to a decrease in weight, HbA1c, and 2-h plasma glucose level in response to an oral glucose tolerance test (OGTT) (9, 10, 11) . Whether these (insulin-sensitizing) effects on glucose metabolism in humans are independent of its impact on body weight is, however, unknown.
The aim of this study was to evaluate the effect of topiramate treatment independent of weight loss in obese insulin-resistant women. To this end, we conducted a study with short-term, low-dose topiramate treatment. Outcome parameters were insulin sensitivity and insulin secretion, measured using a two-step hyperinsulinemic euglycemic clamp with stable isotopes and a hyperglycemic clamp.
Materials and methods

Subjects
Female subjects aged 18-70 years, with a BMI between 27 and 44 kg/m 2 and a homeostasis model of assessment-insulin resistance (HOMA-IR) above 1.7, were eligible for enrollment in the study. Subjects were recruited via advertisements in local newspapers. Exclusion criteria were smoking, recent weight change (O3 kg within the last 3 months), psychiatric disorders or use of antipsychotic/antidepressant drugs, any significant chronic disease (including T2DM), use of medication known to influence glucose metabolism, and difficulties to insert an intravenous catheter. Premenopausal subjects were required to use an approved method of birth control.
This study was conducted in accordance with the Declaration of Helsinki (12) and approved by the local ethics committee. Informed consent was obtained from all subjects. The study was registered under NTR1286 (www.trialregister.nl).
Study design
Subjects were enrolled in a randomized, double-blind, placebo-controlled, cross-over intervention study with a 4-week washout period between the two interventions (T1/2 of topiramateZ21 h). Subjects were randomly assigned to topiramate (to a maximum of 75 mg/day) or placebo as the first intervention, using a standardized randomization list as prepared by a statistician. The study was strictly double blind; subjects as well as study staff were unaware of the order of treatment throughout the whole study period. To minimize side effects, subjects received the following titration schedule for the topiramate treatment: week 1, 25 mg topiramate once daily; week 2, 25 mg twice daily; and weeks 3 and 4, 25 mg in the morning and 50 mg in the evening. During both intervention periods, subjects visited the research center weekly for anthropometric measurements, laboratory tests, and a tablet count for compliance registration. Adverse events were recorded by the research physician by systematic questioning as well as spontaneous self-report. As part of the informed consent procedure, patients received an information letter stating possible side effects of topiramate. Lean body mass was assessed by bioelectrical impedance analysis (Bodystat 1500, Bodystat Ltd., Douglas, Isle of Man, UK). On the last 3 days of both intervention periods, subjects were asked to register their food intake in a diary.
Clamp studies
At the end of each 4-week intervention period, a hyperglycemic clamp (day 27) and a hyperinsulinemic euglycemic clamp (day 28) were performed.
Hyperglycemic clamp b-Cell function in response to glucose was assessed using the hyperglycemic clamp. b-Cell insulin production can be divided into an early phase (0-10 min) and a late phase (80-120 min). After an overnight fast, a priming dose of 20% glucose of 9.6 mg/m 2 was infused in the first 14 min to raise the plasma glucose concentration by 7 mmol/l. Hereafter, a maintenance dose of 20% glucose was infused and the infusion rate was adjusted at 5-min intervals to maintain the plasma glucose level. Blood samples for determining insulin production during the early phase were drawn at 0, 2, 4, 6, 8, and 10 min and at 80, 90, 100, 110, and 120 min for the late phase. The glucose-dependent insulin response (IR), a measure of the b-cell function, was calculated as the increase in insulin from baseline (pmol/l) divided by the increase in glucose from baseline (mmol/l). In addition, the area under the curve (AUC) for insulin was calculated for both the early and the late phase insulin release (13, 14) .
Hyperinsulinemic euglycemic clamp Both hepatic and peripheral insulin sensitivities were measured using the hyperinsulinemic euglycemic clamp, as described previously (15) . In short, after an overnight fast, samples were taken for the measurement of basal levels of glucose, insulin, and background enrichment of [6, 5 .0 mmol/l. In the last 30 min of each 2-h step, blood samples were taken every 10 min to estimate glucose disposal rate and endogenous glucose production (EGP) (16, 17) .
The rates of appearance (R a ) and disappearance (R d ) for glucose were calculated as the tracer infusion rate divided by the tracer-to-trace ratio. The EGP during the two clamp steps was calculated as the difference between the rates of glucose appearance and glucose infusion (18) .
Indirect calorimetry
Indirect calorimetry with a ventilated hood (Oxycon Beta, Mijnhardt Jaegher, Breda, The Netherlands) was performed for 30 min under basal conditions and during the second step of the hyperinsulinemic euglycemic clamp to estimate energy expenditure and substrate oxidation rates. Total glucose and lipid oxidation rates were calculated as described previously (19) . Nonoxidative glucose disposal (NOGD), as a measurement for glycogen storage, was calculated by subtracting the glucose oxidation rate from the R d of glucose. ]-glucose were measured in a single analytical run, using gas chromatography coupled to mass spectrometry as described previously (20, 21) .
Statistical analysis
The primary end point of our study was insulin sensitivity measured as the glucose disposal rate during a hyperinsulinemic euglycemic clamp with stable isotopes. As data on glucose disposal rates for our specific population were not available at the time of protocol writing, sample size was calculated using data on insulin sensitivity as measured by the M-value (i.e. whole-body glucose uptake measured as the glucose infusion rate required to maintain euglycemia during a hyperinsulinemic euglycemic clamp) obtained in 22 nonsmoking obese female patients (22) . We estimated that a sample size of ten subjects would provide 80% power to detect a 15% difference in the primary end point between the two interventions at a two-sided significance level of 0.05 according to the Altman's nomogram for sample size calculations (23) . Taking into account the possibility of dropouts, we wanted to include at least 13 patients in our study.
Results are expressed as meanGS.E.M. The paired Student's t-test was used for comparisons within patients between the two interventions. A nonparametric test (Wilcoxon signed-rank test for paired samples) was applied when appropriate. A P value of !0.05 was considered statistically significant. No adjustment for a potential carryover effect was planned (24) . Statistical analyses were performed using SPSS for Windows (release 18.0, SPSS, Inc., Chicago, IL, USA).
Results
Subjects
A total of 145 subjects were screened for eligibility and 15 subjects met inclusion criteria. Two subjects withdrew informed consent before the start of the study; therefore, 13 subjects were randomized. All subjects completed both intervention periods and there were no dropouts from the study. Subjects were insulin resistant (HOMA-IR 2.0G0.2) and obese with an average BMI of 36.6G1.3 kg/m 2 (except for one subject with a BMI of 29.0 kg/m 2 ). Other baseline characteristics are shown in Table 1 .
Patient characteristics (weight, BMI, and waist circumference) and laboratory values (lipid levels, insulin, and glucose) were similar at the start of study period 1 and the start of study period 2. This is in accordance with the assumption of no carryover effect or period effect.
Anthropometric and laboratory measurements
Body weight was significantly lower after the topiramate period (T: 104.1G4.6 vs P: 103.3G4.6 kg, P!0.05). No significant differences in fat mass and blood pressure were observed after topiramate treatment. Topiramate did not affect plasma glucose concentration in the fasting condition (T: 5.3G0.2 mmol/l vs P: 5.2G0.1 mmol/l; PZNS, Table 1 ). Average food intake during the last 3 days did not differ between the two intervention periods (T: 1831G81 kcal/day vs P: 1743G98 kcal/day; PZNS).
Insulin sensitivity
Plasma glucose levels in both steps of the hyperinsulinemic euglycemic clamp were similar between the two interventions (step 1, T: 5.0G0.1 mmol/l vs P: 5.0G0.1 mmol/l; step 2, T: 4.9G0.1 mmol/l vs P: 4.7G0.1 mmol/l; PZNS). Insulin levels were comparable as well (step 1, T: 121.1G9.0 pmol/l vs P: 128.3G9.7 pmol/l; step 2, T: 305.8G15.0 pmol/l vs P: 323.6G20.2 pmol/l; PZNS).
Peripheral insulin sensitivity was not affected by topiramate; the insulin-stimulated R d of glucose did not significantly differ during both steps of the hyperinsulinemic euglycemic clamp after the two interventions (Fig. 1 ). In addition, there was no difference in EGP between the two treatments (step 1, T: 13.2G0.7 mmol/kg LBM per min vs P: 13.2G0.9 mmol/kg LBM per min; step 2, T: 5.1G0.5 mmol/kg LBM per minvs P: 4.7G0.5 mmol/kg LBM per min; PZNS, Table 2 ). 
Insulin secretion
Average clamp glucose levels during the early phase of the hyperglycemic clamp were similar between interventions. During the late phase, the glucose level was slightly higher in topiramate-treated subjects (T: 12.0G 0.2 mmol/l vs P: 11.6G0.3 mmol/l; P!0.05).
Insulin levels were similar in placebo-and topiramate-treated subjects throughout the 120 min of the hyperglycemic clamp. The AUC of insulin in the early (0-10 min) and late (80-120 min) phase was not different after topiramate treatment. Furthermore, the IRs in both the early (T: 35.5G14.5 pmol/l!mmol/l K1 vs P: 28.1G6.4 pmol/l!mmol/l K1 ; PZNS) and the late (T: 107.4G18.5 vs P: 104.6G23.5 pmol/l! mmol/l K1 ; PZNS) phases were not different (Fig. 2) .
Indirect calorimetry
Both under basal and hyperinsulinemic conditions, there were no differences in glucose and lipid oxidation rates between the two interventions. Resting energy expenditure and NGOD did not differ either ( Table 2) .
Adverse events
The use of topiramate was associated with considerable side effects, as shown in Table 3 . The most common adverse events were related to the nervous system, with paresthesia being the most reported side effect. None of the subjects withdrew because of side effects and no serious adverse events occurred. There were no statistically significant changes in laboratory values, except a 
Discussion
This study shows that short-term, low-dose topiramate treatment (4 weeks, 75 mg/day) does not affect insulin sensitivity and insulin secretion in obese, insulinresistant women and causes typical, bothersome side effects. Despite the low-dose, short-term treatment, subjects did lose a small but statistically significant amount of weight. However, we could not find any effect of topiramate treatment on EGP and glucose disposal, as evaluated by a two-step hyperinsulinemic euglycemic clamp. In animal studies, topiramate has been shown to have an insulin-sensitizing effect (6, 8) ; however, whether this is the case in humans is currently still under debate. Studies in obese subjects have shown that long-term topiramate treatment (24-60 weeks, 64-384 mg/day) leads to significant weight loss (2, 3, 4) and reduces glucose levels in obese patients with epilepsy (25, 26, 27) . Furthermore, topiramate treatment (16-40 weeks, 96-192 mg/day) causes a significant decrease in HbA1c in T2DM patients (9, 10, 11) . These studies also showed that topiramate improves the 2-h plasma glucose level in response to an OGTT (9, 10), suggesting that it ameliorates glucose tolerance. However, these results were achieved in patients who lost a significant amount of weight (K6.0 and K9.1 kg); therefore, it is not known whether these effects on glycemic control parameters are independent of the weight loss effect of topiramate. In addition, Li et al. (28) observed no differences in HOMA-IR after 6 months of topiramate treatment in children with epilepsy (median dosage 2.15 mg/kg/day). In a study of Eliasson et al. (29) in T2DM patients, an improvement in insulin-stimulated glucose disposal (using a hyperinsulinemic euglycemic clamp) could not be detected after 11 months of topiramate treatment (192 mg/day), despite a significant decrease in body weight, fasting plasma glucose, and HbA1c. A trend in enhanced hepatic insulin sensitivity was observed, but this difference did not reach statistical significance, perhaps because of the limited sample size and the relatively high-insulin infusion rate (1 mU/kg per min), which might be expected to suppress hepatic glucose production almost completely. The authors suggested that the effects of topiramate on fasting plasma glucose and HbA1c could be due to a nondetectable improvement in hepatic insulin sensitivity or an improvement in b-cell function. In this study, we used a two-step clamp to get a more accurate estimate of hepatic insulin sensitivity (16, 17) . However, no difference in hepatic insulin sensitivity could be detected.
Even using very accurate methods, we thus could not find an effect of topiramate on insulin sensitivity. This can possibly be explained by the fact that a 4-week treatment period with an escalating dose could be insufficient to show a drug effect. Also, we used a low dose of topiramate, although our dose was high enough to cause some weight loss. Furthermore, Bray et al. (3) showed significant effects of 64 mg topiramate per day on weight and HbA1c comparable to the effect of a dose of 96 mg/day, albeit over a period of 24 weeks. Moreover, our dosage resulted in significant side effects known to be caused by topiramate treatment and it led to a significant, but clinically irrelevant, change in plasma bicarbonate and chloride levels.
To assess b-cell function, we performed a hyperglycemic clamp. Animal studies have shown that topiramate can improve obesity-associated b-cell Table 3 Adverse events during treatment with topiramate vs placebo in obese, insulin-resistant women.
Number of subjects with event (n)
Adverse event
Placebo ( dysfunction (5) . In addition, Frigerio et al. (30) demonstrated that topiramate partially reversed the lipotoxic effect on b-cells, resulting in enhanced insulin secretion. As far as we know, our study is the first human study to formally evaluate the effect of topiramate on b-cell function by a hyperglycemic clamp. A significant impact on glucose-induced insulin release could not be shown, although there was a trend for an increased second-phase AUC of insulin in the topiramate group. However, during this phase, the average serum glucose was significantly higher in the topiramate treatment arm and the IR, which is corrected for the difference in glucose levels, and is similar between the two groups. On the other hand, it cannot be completely excluded that with the study of additional participants, a significant difference will be shown, as we did not power our study on insulin secretion.
Strengths of our study are the randomized, placebocontrolled design, the use of standard assessments for investigating insulin sensitivity, as well as insulin secretion and retention of all study participants. A crossover design has advantages, such as the elimination of between-subject variability. There are also some limitations, for example, the risk of a carryover or a period effect and a risk of subjects dropping out after the first period (31) . Crossover studies can therefore only be used with interventions that have no permanent effect on the outcome parameter and for conditions that do not change spontaneously over time. A carryover effect was not expected because of the washout period and because of the temporary effect of topiramate on insulin sensitivity in the absence of significant weight loss. As clamp studies are costly and time consuming for subjects as well as research staff, it was not feasible to obtain data on insulin sensitivity and secretion at the start of both treatment periods. However, subjects were comparable with respect to other variables, such as fasting glucose and HOMA-IR before the start of both treatment arms. A period effect was also not expected as insulin sensitivity is not expected to change spontaneously over a period of 12 weeks. Also, patient characteristics (weight, BMI, and waist circumference) and laboratory values (lipid levels, insulin, and glucose) were similar at the start of study period 1 and the start of study period 2.
Another limitation of our study is that although the aim of our study was to assess the effect of topiramate treatment independent of weight loss, subjects nonetheless did lose weight during the topiramate treatment period, albeit a small amount. It is currently not fully known how topiramate exerts its effect on body weight, but several mechanisms have been proposed (32) . For example, studies have shown that topiramate decreases food intake in animals as well as in humans (8, 33) . Furthermore, animal studies showed that topiramate treatment can increase energy expenditure and decrease energetic efficiency (34, 35) . This, however, was not demonstrated in humans (33) . Why topiramate causes weight reduction in some patients but not in others is also up for debate. It seems that topiramateinduced weight loss is correlated with baseline BMI, causing a greater amount of weight loss in obese patients. Data on the effect of drug dosage and gender are, however, conflicting (26, 32) . As there was no difference in food intake or energy expenditure between the two interventions in our study, it remains unclear what has caused the decrease in body weight. However, as these were not primary outcome measurements, our study was not powered to detect a difference in food intake or energy expenditure. Another explanation for the weight loss could be an increase in physical activity. Unfortunately, this was not measured in our study.
In conclusion, this study shows that low-dose topiramate treatment for 4 weeks did not have a significant effect on insulin sensitivity or b-cell function in 13 adult females without diabetes and in addition causes bothersome side effects. 
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